Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Formaldehyde induces squamous cell carcinomas in the nasal passages of rats following chronic inhalation exposure at concentrations of > or = 10 ppm. We have examined the complementary
DNA
of the tumor suppressor gene
p53
from 11 primary formaldehyde-induced tumors for mutation using
DNA
sequence analysis. A polymerase chain reaction-amplified fragment of the rat
p53
complementary
DNA
containing the evolutionarily conserved regions II-V was directly sequenced from each tumor. Point mutations in the
p53
complementary
DNA
sequence were found in 5 of 11 of the tumors analyzed. These data demonstrate
p53
point mutations in formaldehyde-induced squamous cell carcinomas and indicate a common alteration in certain rat and human squamous cell carcinomas of the respiratory tract.
...
PMID:p53 mutations in formaldehyde-induced nasal squamous cell carcinomas in rats. 139 39
Wild-type
p53 protein
was shown to bind specifically to
DNA
sequences within SV40 (Bargonetti et al. 1991), the human ribosomal gene cluster (RGC) (Kern et al. 1991a), and the murine muscle creatine kinase gene (MCK) (Zambetti et al. 1992). However, a direct comparison of these three sites was not performed. Here we demonstrate, by filter binding and gel mobility-shift assays, that wild-type
p53
binds with similar affinities to MCK and RGC sites but less tightly to the SV40 site. We examined the effects of two candidate regulators of
p53
function, SV40 large T antigen and oncogenic mutant p53, on the binding of wild-type
p53
to RGC
DNA
. We show that wild-type T antigen prevents
p53
from binding to the RGC site under all conditions tested. Moreover, two temperature-sensitive mutant SV40 T antigens, which fail to transform cells at the nonpermissive temperature, prevent
p53
from binding to the RGC site at the permissive, but not at the restrictive, temperature. The ability of complexes containing wild-type
p53
and tumor-derived mutant p53 proteins to bind to RGC
DNA
varies according to the position of the mutation. Complexes containing wild-type and either his175 or his273 mutant p53 proteins are completely unable to bind to the RGC
DNA
sequence. Interestingly, a complex containing wild-type
p53
and the trp248 mutant p53 characteristic of Li-Fraumeni syndrome patients displays nearly wild-type levels of binding. Perhaps this mutant allele can be tolerated in these individuals because the wild-type mutant p53 complex maintains the ability to bind to
DNA
. Our data indicate that the oncogenic potential of both T antigen and some mutant p53 proteins is the result of their ability to block binding of wild-type
p53
to
DNA
.
...
PMID:Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. 139 68
Human DNA-PK is a nuclear, serine/threonine protein kinase that, when activated by
DNA
, phosphorylates several
DNA
-binding substrates, including the
tumor suppressor protein p53
. To identify which
p53
residues are phosphorylated, we examined DNA-PK's ability to phosphorylate synthetic peptides corresponding to human
p53
sequences. Serines 15 and 37 in the amino-terminal transactivation domain of human
p53
, and serines 7 and 18 of mouse
p53
, were phosphorylated by DNA-PK in the context of synthetic peptides. Other serines in these
p53
peptides, and serines in other
p53
peptides, including peptides containing the serine 315 p34cdc2 site and the serine 392 casein kinase II site, were not recognized by DNA-PK or were phosphorylated less efficiently. Phosphorylation of the conserved serine 15 in human
p53
peptides depended on the presence of an adjacent glutamine, and phosphorylation was inhibited by the presence of a nearby lysine. Phosphorylation of recombinant wild-type mouse
p53
was inhibited at high
DNA
concentrations, suggesting that DNA-PK may phosphorylate
p53
only when both are bound to
DNA
at nearby sites. Our study suggests that DNA-PK may have a role in regulating cell growth and indicates how phosphorylation of serine 15 in
DNA
-bound
p53
could alter
p53
function.
...
PMID:Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. 140 79
We report here the isolation and identification of the RNA specifically immunoprecipitated and covalently linked to the tumor suppressor gene product
p53
. After treatment with proteinase K, the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) band of
p53
yields a single, discrete 157-nucleotide RNA, which was cloned, sequenced, and identified as 5.8S rRNA. 5.8S rRNA was obtained only after proteolysis of the
p53
SDS-PAGE band. Free 5.8S rRNA did not comigrate with
p53
in SDS-PAGE. This RNA was only immunoprecipitated from cells containing
p53
. Protein-free RNA obtained by proteolysis of the
p53
band hybridized to the single-stranded
DNA
vector containing the antisense sequence of 5.8S rRNA. The covalence of the
p53
-5.8S rRNA linkage was demonstrated by the following findings: (i)
p53
and the linked 5.8S rRNA comigrated in SDS-PAGE; (ii) only after treatment of the
p53
-RNA complex with proteinase K did the 5.8S rRNA migrate differently from
p53
-linked 5.8S rRNA; and (iii) this isolated RNA was found linked to phosphoserine, presumably at the 5' end. Covalent linkage to the single, specific RNA suggests that
p53
may be involved in regulating the expression or function of 5.8S rRNA.
...
PMID:p53 is covalently linked to 5.8S rRNA. 140 86
Biologically active mutant p53 from Balb/c mouse tumor cells (Meth A) was analysed for its specific interaction with
DNA
. Restricted phage lambda
DNA
, representing
DNA
of high complexity with regard to sequence and secondary structure, was used to probe for such an activity in a target-bound
DNA
-binding assay, using doubly immunopurified
p53
. A single lambda
DNA
fragment was specifically retained with very high affinity (KD = 10(-10) M). Specific
DNA
binding was shown to be an intrinsic property of
p53
, as it could be blocked with
p53
-specific monoclonal antibodies PAb122 and PAb421. The characteristics of the
DNA
binding of
p53
to this lambda
DNA
fragment, as well as the structural properties of this fragment, suggested the possibility that
p53
might be able to interact with nuclear matrix attachment region (MAR)
DNA
. Indeed, established genomic MAR elements were specifically bound by Meth A
p53
, whereas no binding was observed to an AT-rich control
DNA
. The interaction of
p53
with MAR elements in vitro is compatible with the idea that
p53
in vivo is involved in the regulation of replication and/or expression of cellular
DNA
. Complex
DNA
interactions were not restricted to mutant p53 from Meth A cells. Mutant p53 of a different conformational phenotype (PAb246+ 'wild-type' as opposed to PAb246- 'mutant' for
p53
from Meth A cells) from minimally transformed T3T3 cells, as well as genotypic wild-type
p53
expressed by a recombinant baculovirus in insect cells, exhibited similar
DNA
-binding properties.
...
PMID:Specific and complex interactions of murine p53 with DNA. 140 33
Bronchial epithelial dysplasia is believed to precede invasive squamous cell carcinoma of the lung. Six paired dysplasia and tumour samples were distinguished histologically in sections of formalin-fixed paraffin-embedded lung tissue from patients with lung cancer. Additionally, samples of dysplastic bronchial epithelium were obtained from patients without lung tumours. Microdissection of the unstained sections provided dysplastic and tumour samples from which
DNA
was prepared for comparison with the patients' constitutional genotype, using polymerase chain reaction-based restriction fragment length polymorphism analysis. All six samples of tumour and the paired adjacent samples of bronchial dysplasia showed loss of heterozygosity (LOH) at loci on the short arm of chromosome 3. Five of the six cases showed involvement of the
p53
gene as assessed by LOH at the AccII site within the gene, and by immunoreactivity to CM-1, an antibody which recognizes the mutated form of the
p53 protein
in paraffin-embedded material. Of the dysplastic samples, obtained from patients without invasive tumours, all three showed LOH at 3p; one sample showed LOH at the AccII polymorphic locus within the
p53
gene, and another sample, uninformative at this locus, stained positively with this antibody. These results indicate that somatic genetic changes are present in preinvasive lesions in the bronchus.
...
PMID:p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. 140 39
Mutations of the ras gene family appear to be an uncommon genetic alteration in SCCHN. A common region of
DNA
amplification on chromosome 11q13 has been identified in SCCHN. A cluster of proto-oncogenes (int-2, hst-1, bcl-1, prad-1) has been localized to the 11q13 region. Studies are needed to determine the critical genes in 11q13 whose expression drive the amplicon. Mutations of the
p53 tumor suppressor
gene are the most common genetic alteration in SCCHN. The hope is that dysregulated oncogenes or tumor suppressor genes may be targets for specific therapy.
...
PMID:Genetic alterations in head and neck cancer. 140 91
The expression of the
p53
gene product was investigated immunocytochemically in a retrospective series of 164 formalin-fixed paraffin-embedded invasive breast carcinomas with pathologically proven negative lymph nodes. Overall, 78 tumors (48%) showed a variable degree of
p53
immunoreactivity. Among these, 38 cases were low expressors (1-10%
p53
immunoreactive tumor cells), 21 moderate expressors (10-50% immunoreactive cells) and 19 high expressors (> 50% immunoreactive cells). Abnormal
p53
expression correlated significantly with tumor size, histological and nuclear grade,
DNA
ploidy, mitotic rate and proliferation index, and with the lack of estrogen receptors. Disease-free and adjusted survival analysis of the 124 node-negative patients with long term (more than 10 years) follow-up, however, did not reveal an independent prognostic role for
p53
expression. These data suggest that the evaluation of
p53
immunoreactivity may only play a role in a multiparametric prognostic assessment of node-negative breast carcinoma.
...
PMID:Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. 141 93
Allelic losses on the short arm of chromosome 17 occur frequently in colorectal cancers. Despite the existence of other common molecular events such as loss of the long arms of chromosomes 18 and 5, it has been demonstrated that the former has the greatest prognostic significance. Of the various genes mapping to the commonly deleted sequence, the best candidate as a 'target' seems to be the
p53
antioncogene. We applied our methods of detection of the
p53 protein
in a series of 78 colorectal cancers stored in a tumour bank from 1985 to 1989, for which the median follow-up was 42 months. Nuclear-attached
p53
was quantified by flow cytometry and soluble
p53
was assayed by ELISA. Both assays used a monoclonal antibody considered to be specific for a conformational epitope present only on the mutated protein. Fifty of the 78 tumours (64%) were found to present significant levels of
p53
attached to the nucleus. A further two tumours contained high levels of
p53
only in their soluble fraction. Thus, 52 out of 78 cancers (67%) were considered to be positive for
p53
. The
p53
content correlated with 17p loss (P < 0.002), hyperdiploid
DNA
content (P < 0.001) and tumour site (P < 0.03), but not Dukes' stage (P = 0.15).
p53
negative cases had a better overall survival than
p53
positive ones (P < 0.03). When the 14 stage D tumours were excluded from the analysis,
p53
was no longer significantly predictive of survival (P < 0.07), but remained predictive of recurrence (P < 0.02) and metastasis (P < 0.03). Multivariate analysis was not performed because of the small number of cases. Overall, disease-free and metastasis-free survival were compared to the positivity obtained either with pAb 421 and/or 1801 or pAb 240 since all three were used in the flow cytometric analysis, defining subsets of 421-, 1801+ and 421-, 1801-, 240+. The presence of nuclear protein presenting the mutation-specific epitope, recognised by pAb 240, was found to be the most discriminant. It must be noted that univariate survival analysis demonstrated that more than 80% of patients with
p53
-negative tumours were alive at 3 years vs less than 50% in the
p53
-positive group. A large prospective study should be conducted to define the exact prognostic significance of the
p53
content of colorectal carcinomas.
...
PMID:Increased p53 protein content of colorectal tumours correlates with poor survival. 141 18
We present here an analysis of the spectrum of mutations of the
p53
gene seen in 127 bone and soft tissue sarcomas of various histological classifications. Gross rearrangements were analyzed by Southern blotting using a complementary
DNA
probe from the
p53
gene, and subtle alterations in the entire coding sequence (exons 2 through 11) were identified by a combination of single-strand conformation polymorphism analysis and direct genomic sequencing. A total of 42 somatic alterations of the
p53
gene were found, of which 21 were gross rearrangements and 21 were subtle alterations. These included 17 cases of a single base substitution, 3 small deletions, and one single base insertion. In contrast to reported findings for other types of cancer, we found that mutations of the
p53
gene in sarcomas are quite heterogeneous both in their distribution throughout the gene and in the type of genetic alterations that result. All 13 missense mutations we found occurred at highly conserved residues, whereas 8 nonsense mutations occurred at sites that spanned the gene from codons 46 to 316. Surprisingly, approximately one-half of the osteosarcomas with allelic deletions on 17p did not have detectable alterations in the coding sequence of the
p53
gene.
...
PMID:Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. 142 62
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>